semaglutide advisory committee versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Great discussions. Strong evidence. Better

We break it down for you here.

Background Antipsychotic-induced weight gain (AIWG) represents a significant clinical challenge for both patients and clinicians, requiring appropriate interventions to prevent or reverse weight gain in patients using antipsychotics

Orbicular Pharmaceutical Technologies secures ANDA Tentative Approval for g-Ozempic (Semaglutide Injection) in partnership with Apotex Inc

This drug class is exceeding all expectations, well beyond weight loss, with new clinical trial data this week for heart disease and #Parkinsons A rundown and where we're headed in the new Ground Truths (link in profile) and a companion podcast w/ @DanielJDrucker

Our innovative GLP-1 and Amylin protocols deliver sustainable results